Ferroptosis in cancer cells triggers PGE2 production for tumor immune evasion

Mouse

All mice used in this study were from a C57BL/6J genetic background and obtained from the Jackson Laboratory (JAX). Ptger2−/−Ptger4fl/fl the mice were generated by crossing Ptger2−/− mouse (004376, JAX) to Ptger4fl/fl mice (028102, JAX) and then crossed with Clec9acreate mouse (025523, JAX) to generate Clec9acreatePtger2−/−Ptger4fl/fl mice, crossed with Cd4create mouse (022071, JAX) to generate Cd4createPtger2−/−Ptger4fl/fl mice or crossed with Itgaxcreate mouse (008068, JAX) to generate ItgaxcreatePtger2−/−Ptger4fl/fl mouse. OT-I × CD45.1 mice were generated by crossing OT-I (003831, JAX) mice with CD45.1 (002014, JAX) mice. Unless otherwise noted, all mice used in this study were used on a CD45.2/CD45.2 background. In all experiments, mice aged 8 to 20 weeks were sex-matched and randomly assigned to control or treatment groups. Experiments on mouse tumors with Gpx4−/− tumors as well as T cell depletion were performed without blinding; all other experiments were conducted blinded. No statistical method was used to predetermine sample sizes. Mice were killed by cervical dislocation under anesthesia. All mice were maintained and raised at the Technical University of Munich Klinikum rechts der Isar, under standard conditions, without specific pathogens, with water and food ad libitum, in a controlled environment (22 ± 2 °C, 55 ± 10% humidity, 12 h light-dark cycle) and in accordance with the guidelines of the European Federation of Laboratory Animal Science Associations. All animal experiments were carried out in accordance with the guidelines of the Upper Bavaria District Government (Department 5 – Environment, Health and Consumer Protection).

Cell lines

Control and Ptgs1/Ptgs2−/− BRAF (V600E) melanoma cells were generated using the CRISPR–Cas9 system as previously described21. BRAF(V600E)–OVA and Ptgs1/Ptgs2−/− BRAF(V600E)–OVA variants were generated by lentiviral transduction, as described previously20. 4-OH-TAM-inducible Gpx4−/− immortalized mouse fibroblasts (Pfa1) have already been described43. Gpx4−/− MC38 and Gpx4−/− BRAF(V600E) cells were generated by CRISPR–Cas9-mediated gene editing using the lentiCRISPR v2-puro vector expressing unique guide RNAs as previously described.44. Brief, Gpx4-targeting of the single guide RNA (5′-caccGCGTGTGCATCGTCACCAACG) was cloned into the BsmBI-digested lentiCRISPR v2-puro vector (98290, Addgene) and used to transiently transfect cancer cell lines using the X-tremeGENE HP agent (Roche). One day after transfection, cells were selected using puromycin (5 µg ml−1) and then cultured with Lip-1 (1 µM) to prevent ferroptosis. After selection, single-cell clones were selected and knockout clones were identified by immunoblotting. Map14−/− Cells were generated by CRISPR–Cas9-mediated gene editing using p38α MAPK14 CRISPR–Cas9 knockout plasmid (sc-424051; Santa Cruz) according to the manufacturer’s protocol. After sorting for GFP+ cells, single-cell clones were selected, and knockout clones were identified by immunoblotting. Pfa1, Lewis lung carcinoma (LLC) and Gpx4−/− LLC cells were provided by MC; MC38 and Su86.86 cells were provided by A. Krüger. Small cell lung cancer (SCLC) cell lines were provided by SvK

BRAF(V600E), Ptgs1/Ptgs2−/− BRAF(V600E), BRAF(V600E)-OVA, Ptgs1/Ptgs2−/− BRAF (V600E)–OVA, 4T1, NRAS (G12D), LLC, CT26, SLCL, Pfa1, NIH3T3, A549, Su86.86 and HT-29 cells were cultured in complete RPMI medium (RPMI 1640 medium, Thermo Fisher Scientific) supplemented with 10% FCS (PAN-Biotech), 50 U ml–1 penicillin (Thermo Fisher Scientific) and 50 µg ml–1 streptomycin (Thermo Fisher Scientific). MC38, D4M.3 A, Panc02, mouse pancreatic ductal adenocarcinoma (PDAC) cells, and human patient-derived PDAC cells were cultured in DMEM (Thermo Fisher Scientific) supplemented with 10% FCS, 50 U ml.–1 penicillin and 50 mg ml–1 streptomycin. Gpx4−/− the cells were cultured in their respective medium supplemented with 1 μM Lip-1 to prevent ferroptosis. For in vitro tests, Gpx4−/− cell lines were cultured in 1 µM Ferrostatin-1 (Fer-1) for one passage before seeding with or without Fer-1 to assess ferroptosis and PGE2 production. Unless otherwise noted, all cell viability and PGE analyzes2 production was completed after 24 hours.

To generate conditioned medium for cancer cells, 4 × 105 cancer cells were cultured in 2 ml of complete RPMI or DMEM medium for 24 h before the addition of the ferroptosis inducers RSL3 or ML210 (250 nM for NRAS (G12D), 500 nM for 4T1 and D4M.3A, and 1,000 nM for BRAF (V600E) and MC38 cells), doxorubicin ( 10 µM) or treatment with 150 mJ cm−2 UVB. Eight hours later, cancer cells were washed three times with PBS and cultured for an additional 16 hours in RPMI or complete DMEM. The cell supernatant was collected, centrifuged at 600g for 5 minutes to remove dead cell debris and stored at -20°C until further use. All cell lines were routinely tested in-house for mycoplasma contamination by PCR. No further cell line authentication was performed in the laboratory.

Tumor cell injections

Cancer cell lines were detached by trypsinization (Thermo Fisher Scientific) and washed three times in sterile PBS (Thermo Fisher Scientific). Cells were injected subcutaneously in 100 μl of endotoxin-free PBS into the flank of recipient mice, using 2 × 105 cells for tumor growth studies and 2 × 106 cells for all other experiments. Tumor growth was measured using a digital caliper. The tumor diameters shown in the figures refer to the average values ​​of the longest diameter and its perpendicular for each tumor. Tumor growth was limited to a maximum diameter of 15 mm, which served as a humane endpoint and was not exceeded in any of the experiments. For animals reaching the humane endpoint before the end of the observation period, the last measured tumor diameter was carried forward to subsequent time points (last observation carried forward). For experiments involving ferroptotic control or Ptgs1/Ptgs2−/− BRAF (V600E)–OVA melanoma cells, cancer cells were pretreated with 1 μM RSL3 for 8 h before subcutaneous injection of 1 × 106 cells in 100 µl of endotoxin-free PBS in the flank of recipient mice.

CD8+ T cell exhaustion in vivo

To exhaust the CD8+ T cell, mice received intraperitoneal injections of 100 μl of mouse anti-CD8β antibody (200 μg per mouse; 53-5.8, BioXCell) every 5 days, starting on day 1 following tumor cell inoculation.

In vivo pharmacological treatment

Treatment of mice bearing subcutaneous MC38 or BRAF control (V600E) tumors was initiated once the tumors were palpable, 3 to 5 days after tumor cell transplantation. The solutions were prepared freshly each day. For induction of ferroptosis, mice received a daily intraperitoneal injection of 40 mg kg−1 IKE dissolved in 55% PEG 300 (Sigma) and 45% PBS. Lyophilized CXB (MedChem) was weighed using a fine balance and prepared in a 60:40 ratio of DMSO (1 part, Sigma)/PEG400 (5 parts, Sigma): dH.2O. The final concentration was 6 mg ml−1corresponding to a dose of 30 mg kg−1 delivered in a total volume of 100 µl per mouse. CXB was administered daily by oral gavage.

Treatment of tumor tissue and lymphoid organs

Tumors, lymph nodes, or spleens from mice inoculated with tumor cells were collected at the indicated time points after cancer cell transplantation. The weight of the tumor or organ was measured using a microscale. For flow cytometry analysis, tumor samples were mechanically dissociated and digested with DNase I (100 µg ml-–1Merck) and collagenase IV (200 U ml–1Thermo Fisher Scientific) for 40 min at 37°C, followed by filtration through a 70 µm and 30 µm cell strainer (Miltenyi) and washing with FACS buffer (PBS with 1% FCS and 2 mM EDTA) to generate single-cell suspensions before proceeding with antibody-mediated staining. Spleens were passed through a 70 µm cell strainer, followed by lysis of red blood cells with ACK lysis buffer for 3 min and further filtration using a 30 µm cell strainer. Lymph nodes were dissociated using a 30-µm cell strainer.

Antibodies and reagents for flow cytometry and cell sorting

The following antibodies and staining reagents were used for flow cytometry or cell sorting: eFluor 450 fixable viability dye (dilution: 1:1,000; Thermo Fisher Scientific); fixable viability dye APC-eF780 (1:2,000; Thermo Fisher Scientific); PE-Cy7 anti-CD8α (1:200; 53-6.7, BioLegend); PE-Dazzle594 anti-CD8α (1:200; 53-6.7, BioLegend); BV711 anti-mouse/human-CD44 (1:100; IM7, BioLegend); anti-mouse/human-CD44 PerCP-Cy5.5 (1:100; IM7, BioLegend); anti-CD45.1 PE (1:100; A20, BioLegend); BV510 anti-CD45.2 (1:100; 104, BD Biosciences); BUV395 anti-CD45.2 (1:100; 104, BD Biosciences); FITC anti-CD62L (1:100; MEL-14, BioLegend); FITC anti-CD103 (1:100; M290, BD Biosciences); Pe-Cy7 anti-CD103 (1:100; 2E7; BioLegend); PE-Dazzle594 anti-CD186/CXCR6 (1:200; SA051D1, BioLegend); BV421 anti-CD366/TIM-3 (1:200; RMT3-23, BioLegend); BV605 anti-CD279/PD-1 (1:100; 29F.1A12, BioLegend); PerCP/Cy5.5 anti-TCRβ (1:100; H57-597, BioLegend); AF700 anti-TCRβ (1:100; H57-597, Sony); Anti-human GZMB APC (1:200; GB12, Thermo Fisher Scientific); Anti-human GZMB PE (1:200; GB12; Thermo Fisher Scientific); FITC anti-Ki-67 (1:100; SolA-15, Thermo Fisher Scientific); anti-mouse TCF1 PE (1:200; S33-966, BD Biosciences); and rabbit-anti-mouse-TCF1/TCF7 (1:100; C.725.7, Thermo Fisher Scientific). This was followed by staining with donkey anti-rabbit IgG AF647 (1:200; Poly4064, BioLegend); BV605 anti-CD11b (1:200; M1/70; BioLegend); PerCP-Cy5.5 anti-CD11c (1:200; N418; BioLegend); PE-Cy7 anti-CD11c (1:200; M17/4; BioLegend); BV421 anti-XCR1 (1:200; ZET; BioLegend); anti-CXCL9 PE (1:100; MIG-2F5.5, BioLegend); PerCP/Cy5.5 anti-IL-12/IL-23 p40 (1:100; C15.6, BioLegend); FITC anti-IA/IE (MHC class II) (1:1,000; M5/114.15.2, Thermo Fisher Scientific); AF700 anti-mouse H-2kb (1:100; AF6-88.5, BioLegend); AF647 anti-CD86 (1:200; GL-1, BioLegend); BV605 anti-CD80…

Gn Health

Logo